Robert Stefanovich Sells 38,700 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 38,700 shares of CryoPort stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $7.76, for a total value of $300,312.00. Following the completion of the sale, the chief financial officer directly owned 255,701 shares in the company, valued at $1,984,239.76. This represents a 13.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 16th, Robert Stefanovich sold 2,743 shares of CryoPort stock. The stock was sold at an average price of $8.00, for a total value of $21,944.00.

CryoPort Trading Up 2.3%

Shares of CYRX traded up $0.18 during mid-day trading on Monday, hitting $8.00. The company’s stock had a trading volume of 578,199 shares, compared to its average volume of 400,853. CryoPort, Inc. has a 1-year low of $4.63 and a 1-year high of $11.45. The firm has a market capitalization of $398.88 million, a P/E ratio of 6.06 and a beta of 1.69. The firm has a 50-day simple moving average of $9.23 and a 200 day simple moving average of $9.36.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. As a group, sell-side analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Mak Capital One LLC purchased a new stake in shares of CryoPort in the 3rd quarter worth about $7,756,000. UBS Group AG raised its position in CryoPort by 112.7% during the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after acquiring an additional 705,649 shares during the last quarter. Millennium Management LLC raised its position in CryoPort by 23.8% during the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after acquiring an additional 623,896 shares during the last quarter. Kennedy Capital Management LLC purchased a new stake in shares of CryoPort in the second quarter valued at about $4,084,000. Finally, Assenagon Asset Management S.A. grew its position in shares of CryoPort by 37.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock valued at $14,208,000 after purchasing an additional 408,263 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC increased their price target on shares of CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen lowered shares of CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, CryoPort has a consensus rating of “Moderate Buy” and a consensus target price of $12.94.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.